ASACOL 800 TABLET (DELAYED-RELEASE)

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

MESALAZINE

Disponibbli minn:

ALLERGAN INC

Kodiċi ATC:

A07EC02

INN (Isem Internazzjonali):

MESALAZINE

Dożaġġ:

800MG

Għamla farmaċewtika:

TABLET (DELAYED-RELEASE)

Kompożizzjoni:

MESALAZINE 800MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

180

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

ANTI-INFLAMMATORY AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0116808010; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

2021-01-27

Karatteristiċi tal-prodott

_ _
_Page 1 of 26_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ASACOL
TM 800
Mesalamine Tablets (Delayed-Release) *
Tablets, 800 mg, Oral
Mfr. Std.
Lower Gastrointestinal Anti-inflammatory
Allergan Inc.
85 Enterprise Blvd., Suite 500
Markham, Ontario
L6G 0B5
www.allergan.ca
Date of Initial Approval:
April 26, 2005
Date of Revision:
March 18, 2021
Submission Control No: 245722
* also referred to as 5-aminosalicylic acid (5-ASA)
_ _
_ _
_Page 2 of 26_
RECENT MAJOR LABEL CHANGES
WARNINGS AND PRECAUTIONS, Renal
04/2020
WARNINGS AND PRECAUTIONS, Acute Intolerance Syndrome
03/2021
WARNINGS AND PRECAUTIONS, 7.1.2 Breast-feeding
03/2021
TABLE OF CONTENTS
RECENT MAJOR LABEL CHANGES
........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................. 4
1
INDICATIONS
.................................................................................................................
4
1.1
Pediatrics
...............................................................................................................
4
1.2
Geriatrics
...............................................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
........................................................ 5
4
DOSAGE AND
ADMINISTRATION.................................................................................
5
4.1
Dosing Considerations
...........................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
....................................................... 5
4.3
Administration
.............................................................